Meitheal Pharmaceuticals Secures FDA Approval for Garzulys™ Biosimilar Insulin to Expand Diabetes Care in the U.S.
Meitheal Pharmaceuticals, Inc., a Chicago-based biopharmaceutical company focused on the development and commercialization of generic injectable medicines, biologics, fertility therapies, and branded pharmaceutical products, has announced a significant milestone with the U.S. Food and Drug Administration (FDA) approval of Garzulys™ (insulin aspart-fsan) injection, a biosimilar to NovoLog® (insulin aspart). The approval marks another important step in the company’s strategy to expand its biologics portfolio while increasing access to high-quality and more affordable treatment options for patients living with diabetes.
Although Emerge Bioscience Pte. Ltd. is the holder of the approved Biologics License Application (BLA), Meitheal serves as the product’s U.S. Regulatory Agent and has secured exclusive commercialization rights for Garzulys in the United States through its licensing agreement with Emerge.
A Major Expansion into Diabetes Care
The FDA approval of Garzulys represents an important achievement for Meitheal as it continues evolving beyond its established generic injectable business into biologics and specialty medicines.
Garzulys is a rapid-acting human insulin analog indicated to improve glycemic control in both adults and pediatric patients diagnosed with diabetes mellitus. The biosimilar is approved for administration through both subcutaneous injection and intravenous infusion, offering flexibility across multiple treatment settings.
Rapid-acting insulin products are essential components of diabetes management because they help control blood glucose spikes that occur after meals. By offering a biosimilar alternative to NovoLog, Garzulys is expected to provide healthcare providers and patients with an additional treatment option that may help improve accessibility while maintaining comparable clinical performance.
Extensive Global Collaboration Led to FDA Approval
The successful approval of Garzulys is the result of an international collaboration involving multiple organizations, each contributing specialized expertise throughout the product’s development.
Tonghua Dongbao Pharmaceutical Co., Ltd. led the development of the insulin drug substance, while Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF) was responsible for developing the finished drug product.
Clinical development activities were directed by Xentria, Inc., which designed and managed the studies necessary to demonstrate biosimilarity and support regulatory submissions.
Meitheal played a central role throughout the U.S. approval process by leading regulatory strategy and communications with the FDA. As the designated U.S. Regulatory Agent, the company coordinated the submission activities that ultimately resulted in FDA approval.
Meanwhile, Emerge Bioscience serves as the official BLA holder and oversees important supply chain responsibilities associated with manufacturing and product distribution.
The collaboration reflects a growing trend within the pharmaceutical industry where global partnerships leverage specialized expertise across research, manufacturing, clinical development, regulatory affairs, and commercialization.
Strengthening Meitheal’s Biologics Portfolio
Since launching operations in 2017, Meitheal Pharmaceuticals has rapidly expanded its product portfolio.
The company currently supports more than 80 FDA-approved products spanning multiple therapeutic areas, including:
- Oncology
- Anti-infectives
- Critical care
- Anesthesia
- Fertility
- Diabetes
- Hospital medicines
- Biologics
Garzulys further strengthens Meitheal’s position within diabetes care and represents one of the company’s most important biologic approvals to date.
Company leadership views the approval as validation of years of investment in regulatory expertise, scientific capabilities, and international strategic partnerships.
Leadership Highlights Long-Term Strategy
Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals, emphasized that the approval aligns with the company’s broader long-term vision.
According to Shea, Garzulys demonstrates Meitheal’s ability to successfully manage highly complex biologic development programs while building the commercial infrastructure necessary to bring these medicines to U.S. healthcare providers and patients.
He noted that the company’s leadership throughout the FDA regulatory process illustrates Meitheal’s growing capabilities beyond traditional generic pharmaceuticals.
Rather than focusing solely on generic injectable products, the organization continues investing in biologics, specialty medicines, and branded pharmaceutical products that address significant healthcare needs.
Expanding Access Through Biosimilars
Biosimilars have become an increasingly important part of modern healthcare by providing alternatives to reference biologic medicines after patent exclusivity expires.
Unlike traditional generic drugs, biosimilars are developed from living cells and undergo extensive analytical, clinical, and manufacturing evaluations to demonstrate they are highly similar to the FDA-approved reference product.
The FDA approval process requires evidence that no clinically meaningful differences exist between the biosimilar and the reference medicine regarding:
- Safety
- Effectiveness
- Purity
- Potency
- Quality
- Clinical performance
Garzulys met these regulatory standards, allowing healthcare professionals to prescribe it as a biosimilar alternative to NovoLog for approved indications.
The availability of additional biosimilar insulin products may contribute to increased competition in the marketplace, potentially improving patient access and affordability while maintaining high standards of clinical care.
Ongoing Insulin Development Programs
Garzulys is only one component of a broader insulin collaboration established in 2023 between Tonghua Dongbao and Nanjing King-Friend Biochemical Pharmaceutical.
The agreement also includes development of two additional insulin biosimilar candidates currently progressing through development.
Through its exclusive licensing arrangement with Emerge Bioscience, Meitheal retains exclusive U.S. commercialization rights not only for Garzulys but also for these future insulin biosimilar products.
This pipeline positions the company for continued expansion within diabetes care over the coming years.
Approved Uses of Garzulys
Garzulys is indicated to improve blood glucose control in adults and children diagnosed with diabetes mellitus.
As a rapid-acting insulin analog, the medication is designed to help regulate blood sugar levels during meals and is suitable for administration by:
- Subcutaneous injection
- Intravenous infusion when clinically appropriate
Healthcare professionals determine appropriate dosing based on individual patient requirements, glucose monitoring results, dietary habits, and overall diabetes management plans.
Important Safety Information
Like all insulin therapies, Garzulys carries important safety considerations that healthcare providers and patients should carefully review before treatment.
The medication should not be used in patients experiencing episodes of hypoglycemia or in individuals with a known hypersensitivity to insulin aspart or any component of the formulation.
Risk of Hypoglycemia
Hypoglycemia remains the most common adverse reaction associated with insulin therapy.
Severe hypoglycemia may result in:
- Loss of consciousness
- Seizures
- Serious injury
- Death if untreated
Patients should monitor blood glucose regularly and recognize symptoms such as sweating, shakiness, confusion, hunger, dizziness, rapid heartbeat, and weakness.
Medication Errors
Healthcare providers advise patients to carefully verify insulin labels before every injection to avoid accidental substitution with other insulin products.
Sharing insulin pens, syringes, or needles between individuals should never occur due to the risk of transmitting blood-borne infections.
Allergic Reactions
Although uncommon, severe allergic reactions including anaphylaxis can occur with insulin products.
Patients should seek immediate medical attention if they experience:
- Difficulty breathing
- Swelling of the face or throat
- Rapid heartbeat
- Severe rash
- Dizziness
Additional Precautions
Patients should also be monitored for:
- Hypokalemia (low potassium)
- Injection-site reactions
- Lipodystrophy
- Fluid retention when used with certain diabetes medications
- Hyperglycemia due to insulin pump malfunction
Healthcare providers may recommend additional blood glucose monitoring whenever insulin regimens are adjusted.
Common Adverse Reactions
Frequently reported side effects associated with Garzulys include:
- Hypoglycemia
- Injection-site reactions
- Rash
- Itching
- Allergic reactions
- Lipodystrophy
As with all insulin products, treatment should be individualized according to patient needs.
Building a Broader Future
The approval of Garzulys reflects Meitheal Pharmaceuticals’ broader ambition to become a significant participant in the biologics marketplace while maintaining its established leadership in injectable medicines.
By combining regulatory expertise, international partnerships, clinical development capabilities, and commercial infrastructure, the company is building a diversified portfolio that extends across multiple therapeutic categories.
With additional insulin biosimilars already under development and continued investments in biologic medicines, Meitheal aims to further expand treatment options for patients while supporting healthcare providers with high-quality alternatives across a growing range of diseases.
The FDA approval of Garzulys therefore represents not only a new treatment option for diabetes management but also a strategic milestone in Meitheal’s ongoing transformation into a diversified biopharmaceutical company with an expanding presence in the U.S. biologics market.
ABOUT MEITHEAL PHARMACEUTICALS, INC.
Founded in 2017 and headquartered in Chicago, Meitheal Pharmaceuticals, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of generic injectable, biologic, fertility and branded products. Meitheal currently markets more than 80 FDA-approved products across therapeutic areas including anti-infectives, oncology, anesthesia, diabetes, critical care and fertility.
Meitheal combines an established U.S. commercial platform with regulatory expertise and strategic development and manufacturing partnerships to support complex pharmaceutical products. Building on its foundation in generic injectables, the company is making deliberate, long-term investments to expand its biologics and branded portfolio and broaden access to high-quality, fairly priced medicines.
Meitheal is guided by the traditional Irish principle for which it is named—working together toward a common goal, for the greater good.
Learn more at www.meithealpharma.com.
ABOUT TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
Founded in 1985 and based in Jilin Province, China, Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao”) is a biopharmaceutical company specializing in the research, development, manufacturing and commercialization of therapies for diabetes and other endocrine and metabolic diseases. In 1998, Tonghua Dongbao developed China’s first domestically produced recombinant human insulin. The company’s portfolio and pipeline include human insulin, insulin analogs, GLP-1 receptor agonists and other therapies for diabetes and related metabolic conditions. Tonghua Dongbao is publicly listed on the Shanghai Stock Exchange under stock code 600867.
ABOUT EMERGE BIOSCIENCE PTE. LTD.
Established in 2024 and based in Singapore, Emerge Bioscience Pte. Ltd. (“Emerge”) is a subsidiary of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (“NKF”) that supports NKF’s international pharmaceutical trading and supply-chain activities. Emerge coordinates with manufacturers, regulatory authorities, logistics providers and commercial partners to support the reliable, compliant and timely delivery of pharmaceutical products and NKF’s broader international growth strategy.
ABOUT NANJING KING-FRIEND BIOCHECMICAL PHARMACEUTICAL CO., LTD.
Founded in 1986 and headquartered in Nanjing, China, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (“NKF”) is an integrated biopharmaceutical company engaged in the research, development and manufacturing of active pharmaceutical ingredients and finished dosage forms. Building on its established expertise in heparin APIs and sterile injectable products, NKF has expanded its capabilities across generic, biologic and branded products in therapeutic areas including oncology, critical care, fertility and diabetes. NKF supports products and partners in the United States, China, Europe and other global markets and is publicly listed on the Shanghai Stock Exchange under stock code 603707.
ABOUT XENTRIA, INC.
Established in 2020, Xentria Inc. (“Xentria”) works across life science communities creating innovative and authentic collaborations and partnerships that advance challenging drug development. Xentria, derived from “centrality”, is dedicated to delivering customized approaches to ambitious drug innovation through meaningful patient engagement and effective partnerships. Headquartered in Chicago, Xentria is taking the lead to support surging life sciences initiatives for global audiences, while nurturing diversity, individualism, and sustainability.